Skip to main content
Premium Trial:

Request an Annual Quote

Correlia Biosystems Closes $7M Series A Round

NEW YORK – Proteomics firm Correlia Biosystems said on Friday that it has closed a $7 million Series A funding found.

The company said that the round, which was led by Neotribe Ventures and was joined by Cota Capital, the Regents of the University of California, and others, will support the commercial launch of the company's miniaturized ELISA platform.

By miniaturizing ELISA testing, Correlia reduces the time and sample volume required to run these commonly used protein assays.

"With this new funding round, we are poised to bring our unique, more granular assay capabilities to customers who have been waiting for major advances in the 50-year old ELISA market," Correlia CEO Akwasi Apori said in a statement.

"We are excited to join Correlia's journey to create a category-creating new standard for ultra-efficient and highly automated protein biomarker measurement," Swaroop Kolluri, founder and managing director of Neotribe, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.